Last updated: August 28, 2026
NITYR is a specialty orphan drug containing nitisinone for hereditary tyrosinemia type 1, a rare inherited disorder that can cause severe liver and kidney disease. Cycle Pharmaceuticals commercializes NITYR in the United States after FDA approval in 2017. Its market is small in patient count but economically attractive because treatment is chronic, disease-specific, and supported by orphan-drug pricing.
NITYR’s commercial trajectory depends less on broad prescription growth than on patient identification, diagnosis, treatment persistence, reimbursement access, and competition from Orfadin and other nitisinone products. Cycle Pharmaceuticals is privately held, so NITYR-specific revenue, gross margin, and profitability are not publicly disclosed. Public regulatory data support a durable niche franchise, but they do not support a precise standalone revenue forecast.
What is NITYR and what disease does it treat?
NITYR is an oral nitisinone product approved for the treatment of hereditary tyrosinemia type 1, also called HT-1. The disease is caused by impaired tyrosine metabolism and can lead to accumulation of toxic metabolites, liver failure, renal tubular dysfunction, neurologic crises, and hepatocellular carcinoma.
NITYR is supplied as immediate-release tablets in 2 mg, 5 mg, and 10 mg strengths. The FDA-approved labeling recommends use with dietary restriction of tyrosine and phenylalanine. Dosing is weight-based and generally administered twice daily, although clinical management depends on patient age, response, and laboratory monitoring. [1]
Nitisinone inhibits 4-hydroxyphenylpyruvate dioxygenase, reducing the formation of toxic downstream metabolites. It is a chronic treatment rather than a short-course therapy. Patients who respond generally remain on therapy for long periods, creating high persistence and relatively predictable drug utilization.
What is the FDA regulatory status of NITYR?
The FDA approved NITYR on July 26, 2017, under New Drug Application 209449. The product received orphan-drug designation for HT-1. [2]
| Regulatory attribute |
NITYR status |
| Active ingredient |
Nitisinone |
| Indication |
Hereditary tyrosinemia type 1 |
| FDA approval |
July 26, 2017 |
| NDA |
209449 |
| Dosage form |
Immediate-release tablets |
| Strengths |
2 mg, 5 mg, 10 mg |
| FDA pathway |
505(b)(2) NDA |
| Orphan-drug status |
Yes |
| Sponsor/commercial company |
Cycle Pharmaceuticals |
| Administration |
Oral, weight-based, generally twice daily |
The 505(b)(2) pathway allowed the applicant to rely in part on previously established information concerning nitisinone while supporting the specific NITYR formulation and labeling. This pathway is common for reformulated, repurposed, or otherwise differentiated products with an existing active ingredient.
When did NITYR lose orphan exclusivity?
NITYR received seven years of U.S. orphan-drug exclusivity beginning on its approval date. The primary exclusivity period therefore ran to July 26, 2024, subject to the scope of the orphan indication and statutory exceptions. [2]
Orphan exclusivity prevents FDA approval of the same drug for the same indication during the protected period, with exceptions that include drug shortages and inability of the sponsor to assure sufficient quantities. It does not prevent all competing products, and it does not create a permanent barrier to generic or 505(b)(2) competition.
The end of orphan exclusivity increases the probability of competitive entry, but commercial entry still depends on:
- FDA approval of a competing nitisinone product;
- Orange Book patent certifications;
- formulation and bioequivalence requirements;
- payer coverage and substitution policy;
- limited market size;
- manufacturing economics;
- patient and prescriber switching behavior.
For a rare-disease product, the expiration of orphan exclusivity does not necessarily produce an immediate price collapse. A small patient population may support only a limited number of commercially viable suppliers.
What patents protect NITYR?
NITYR’s principal commercial protection has historically come from orphan exclusivity, regulatory approval, product differentiation, and the operational infrastructure required to serve HT-1 patients. Nitisinone itself is an old active ingredient, so composition-of-matter protection for the molecule is not the central barrier.
Potential patent protection can instead relate to:
- tablet composition;
- excipient selection;
- dissolution and stability;
- manufacturing processes;
- dosage forms;
- methods of treating HT-1;
- packaging or administration systems.
The FDA Orange Book is the controlling source for patents submitted for an approved NDA. Patent listings can change through corrections, delistings, patent-term calculations, and litigation. A definitive current assessment requires review of the live Orange Book entry for NDA 209449 and the associated patent records.
The strategic implication is clear: NITYR’s estate is more vulnerable to formulation substitution than a product protected by a broad, unexpired compound patent. A competitor that can demonstrate pharmaceutical equivalence or obtain approval through an appropriate 505(b)(2) or abbreviated pathway may have a credible route to market after regulatory exclusivity ends.
What is the Orange Book status of NITYR?
NITYR is listed in the FDA Orange Book as an approved prescription drug under NDA 209449. The product is distinct from Orfadin, another FDA-approved nitisinone product marketed by Swedish Orphan Biovitrum, commonly known as Sobi. [3]
Orange Book analysis should distinguish among:
- NITYR’s listed drug status;
- patents listed against NDA 209449;
- patents listed against competing nitisinone products;
- exclusivity codes and expiration dates;
- therapeutic equivalence ratings for any approved competitors.
The end of orphan exclusivity does not automatically establish an AB-rated generic equivalent. A product may be approved but not therapeutically equivalent to NITYR, particularly when dosage form, formulation, labeling, or bioequivalence standards differ.
Which companies compete with NITYR?
The principal branded competitor is Orfadin, marketed by Sobi. Both products contain nitisinone and target HT-1. Competition is based on availability, dosing strengths, reimbursement, patient support, supply reliability, and physician familiarity rather than broad clinical differentiation.
| Product |
Company |
Active ingredient |
Primary market role |
| NITYR |
Cycle Pharmaceuticals |
Nitisinone |
U.S. branded HT-1 therapy |
| Orfadin |
Swedish Orphan Biovitrum |
Nitisinone |
Originator and branded competitor |
| Other nitisinone products |
Various potential manufacturers |
Nitisinone |
Possible post-exclusivity competition |
Orfadin received earlier U.S. approval and has a long-established position in metabolic disease treatment. NITYR entered as a competing nitisinone product with its own tablet presentation and commercial strategy.
The market has several structural limits. HT-1 is rare, treatment is concentrated among metabolic specialists, and diagnosis requires specialized testing. As a result, commercial share shifts may be more important than market expansion.
What is the market size for NITYR?
HT-1 is a rare disease with incidence estimates commonly reported around one case per 100,000 births, although prevalence varies by geography and is higher in certain populations. [4] The treated U.S. population is likely measured in the low thousands or below, rather than in tens of thousands.
Market size is determined by four variables:
| Market driver |
Effect on NITYR |
| Newborn screening |
Increases early diagnosis and treatment initiation |
| Lifelong treatment |
Supports high patient persistence |
| Weight-based dosing |
Creates higher utilization as pediatric patients grow |
| Rare-disease pricing |
Supports high revenue per treated patient |
Newborn screening is the most important expansion mechanism. Earlier diagnosis can reduce severe clinical events and increase the number of patients who begin therapy before irreversible liver damage occurs. It can also improve treatment continuity because patients are identified before presenting with acute disease.
The market is not highly elastic. Even if price rises, most diagnosed patients require treatment. Payers, however, can use prior authorization, specialty-pharmacy controls, step edits, and preferred-product policies to influence product selection.
How does NITYR compare with Orfadin?
NITYR and Orfadin have the same active ingredient and the same core HT-1 treatment objective. The competitive distinction is primarily commercial and formulation-based.
| Factor |
NITYR |
Orfadin |
| Active ingredient |
Nitisinone |
Nitisinone |
| Disease |
HT-1 |
HT-1 |
| U.S. market entry |
2017 |
Earlier originator entry |
| Commercial position |
Challenger/alternative brand |
Established branded product |
| Core differentiation |
Product presentation, access, support, contracting |
Historical market presence and physician familiarity |
| Patient switching barrier |
Clinical continuity and prescriber preference |
Same |
| Main risk |
Generic or alternative nitisinone entry |
Generic or alternative nitisinone entry |
Because the two products share the same active ingredient, clinical differentiation is limited. Commercial execution, supply reliability, reimbursement terms, and patient-support services are more important than novel pharmacology.
What Paragraph IV challenges and litigation affect NITYR?
Publicly available regulatory information does not establish a major, widely reported Paragraph IV litigation event against NITYR comparable to litigation surrounding major mass-market drugs.
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. For NITYR, any meaningful challenge would likely focus on formulation or product-specific patents rather than the nitisinone molecule itself.
Potential litigation outcomes include:
- a negotiated launch date;
- settlement with a license;
- launch at risk;
- patent invalidation;
- injunction or delayed entry;
- approval without therapeutic equivalence.
The small market can discourage prolonged litigation because the expected revenue pool is limited. At the same time, high annual treatment value per patient can justify a challenge by a specialty-generic manufacturer with an efficient supply chain.
What generic launch risks exist for NITYR?
The principal post-2024 risk is a competing nitisinone product that wins payer preference or offers a meaningful discount. The risk is gradual rather than necessarily immediate.
Low-volume specialty-generic economics
Manufacturers must recover regulatory, manufacturing, pharmacovigilance, distribution, and market-access costs from a small patient population. This limits the number of likely entrants.
Product switching constraints
HT-1 patients require laboratory monitoring and coordinated dietary management. Physicians may hesitate to switch stable patients unless the alternative has clear reimbursement or supply advantages.
Reimbursement leverage
Specialty pharmacies and insurers can accelerate substitution through formulary placement. A competitor with a lower net price could take share even without a major clinical advantage.
Manufacturing requirements
Nitisinone products require controlled quality, dose uniformity, stability, packaging, and supply continuity. Manufacturing complexity is lower than for a biologic, but the small market increases the financial impact of inventory shortages and batch failures.
Is there biosimilar risk for NITYR?
NITYR has no biosimilar risk because it is a small-molecule drug, not a biologic. The relevant competitive pathways are generic-drug approval, 505(b)(2) approval, and potential branded nitisinone products.
This distinction matters commercially. Biosimilar entry often involves interchangeability, provider-administered biologics, and complex manufacturing. NITYR competition is more likely to involve oral-product bioequivalence, formulation patents, and pharmacy benefit management.
What is NITYR’s financial trajectory?
Cycle Pharmaceuticals does not publicly report audited NITYR revenue as a standalone line item. The company is privately held, and available public regulatory documents do not provide product-level sales, gross profit, prescription volume, or patient counts.
The financial trajectory can therefore be assessed through market structure rather than reported revenue.
| Financial factor |
Expected direction |
| Patient volume |
Gradual growth from diagnosis and newborn screening |
| Revenue per patient |
High, subject to payer discounts |
| Treatment duration |
Long-term or lifelong for many patients |
| Gross-margin profile |
Potentially attractive for an oral specialty product |
| Near-term growth |
Dependent on patient acquisition and share against Orfadin |
| Post-exclusivity risk |
Higher price and share pressure |
| Revenue volatility |
Low from chronic demand, higher from contracts and access changes |
NITYR likely has a concentrated revenue base. A relatively small number of patients can account for a large share of total sales, which creates both financial efficiency and customer concentration risk.
Revenue growth before and around the end of orphan exclusivity would likely come from:
- new diagnoses;
- conversion from Orfadin;
- improved reimbursement;
- broader specialty-pharmacy access;
- population growth among treated pediatric patients;
- international expansion where approved.
After exclusivity, revenue may remain stable if Cycle retains patients through access programs and contracting. The downside case involves a lower-priced competitor securing preferred payer status and causing rapid erosion in new starts and refills.
What licensing deals support NITYR?
Cycle Pharmaceuticals acquired or obtained rights associated with NITYR from Dr. Reddy’s Laboratories. The NITYR product was developed as a nitisinone tablet for the U.S. HT-1 market, and Cycle has commercialized it as part of its rare-disease portfolio. Public disclosures do not provide a complete product-level accounting of royalty rates, milestones, or transfer pricing.
The commercial value of the arrangement is based on access to an established orphan indication without the cost and risk of discovering a new molecule. The principal economic liabilities are likely to include manufacturing costs, regulatory maintenance, commercialization expense, and any contractual payments to development or manufacturing partners.
How strong is the NITYR patent estate?
NITYR has a moderate commercial protection profile rather than a high-strength patent moat.
Its strengths are:
- chronic use;
- high unmet need;
- specialist prescribing;
- low patient switching frequency;
- orphan-disease economics;
- limited likely entrant pool;
- established regulatory and distribution infrastructure.
Its weaknesses are:
- old active ingredient;
- small-molecule competition;
- expiration of core orphan exclusivity in 2024;
- potential formulation-design-around opportunities;
- lack of a broad compound patent barrier;
- limited clinical differentiation from Orfadin.
NITYR is therefore best viewed as a durable specialty franchise with meaningful cash-generation potential, but not as a long-duration exclusivity asset comparable to a newly launched patented therapy.
What generic launch scenarios should investors monitor?
Base case: gradual erosion
One or a small number of nitisinone competitors enters, discounts modestly, and captures selected payer accounts. NITYR retains a substantial share among established patients because of physician familiarity and patient-support programs.
Downside case: preferred-product displacement
A competitor secures favorable formulary status and forces switching through reimbursement controls. NITYR experiences declining new starts, lower refill volume, and net-price compression.
Upside case: market expansion with stable share
Newborn screening and improved diagnosis increase the treated population. Cycle preserves its share through access agreements, supply reliability, and specialist engagement.
What geographic markets matter for NITYR?
The United States is strategically important because it combines high rare-disease treatment value with centralized FDA and Orange Book regulation. Other markets depend on country-specific approvals, pricing controls, health technology assessment, and reimbursement systems.
International expansion can increase patient volume but may produce lower net prices. Europe has established rare-disease infrastructure and existing nitisinone experience, while emerging markets may have underdiagnosis and limited reimbursement.
Key Takeaways
- NITYR is an oral nitisinone treatment for hereditary tyrosinemia type 1.
- Cycle Pharmaceuticals received FDA approval on July 26, 2017, under NDA 209449.
- The seven-year U.S. orphan-drug exclusivity period generally ended July 26, 2024.
- NITYR competes mainly with Sobi’s Orfadin and potential generic or 505(b)(2) nitisinone products.
- The active ingredient is old, so formulation, regulatory, commercial, and access protections matter more than molecule-level patent protection.
- NITYR has no biosimilar risk because it is a small-molecule drug.
- Cycle Pharmaceuticals does not publicly disclose standalone NITYR revenue or profitability.
- The financial outlook is supported by chronic treatment, high revenue per patient, and specialist prescribing.
- The main downside is post-exclusivity price and market-share erosion from a payer-favored competitor.
- Newborn screening, patient identification, and reimbursement access are the main market-expansion drivers.
FAQs
Is NITYR the same drug as Orfadin?
Both contain nitisinone and treat hereditary tyrosinemia type 1, but they are separate branded products with different sponsors, formulations, approvals, and commercial strategies.
Is NITYR considered a generic drug?
No. NITYR was approved as a 505(b)(2) new drug application rather than as an ordinary ANDA generic. Its regulatory status and therapeutic-equivalence treatment depend on the FDA approval record and Orange Book listings.
Can patients switch from Orfadin to NITYR?
A switch may be clinically possible because both products contain nitisinone, but treatment changes should be managed by the treating metabolic-disease specialist. Product-specific dosing, formulation, supply, and reimbursement factors can affect the decision.
Does NITYR have pediatric exclusivity?
The standard NITYR approval information identifies orphan-drug exclusivity. Pediatric exclusivity is a separate FDA incentive and should not be presumed without a specific FDA designation or Orange Book entry.
What is the biggest investment risk for NITYR?
The biggest risk is commercial erosion after orphan exclusivity, especially if a lower-priced nitisinone product receives favorable payer placement and captures new patients or forces switches among existing patients.
References
-
U.S. Food and Drug Administration. (2017). NITYR (nitisinone) tablets prescribing information. FDA.
-
U.S. Food and Drug Administration. (2017). NITYR approval letter, NDA 209449. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Orphanet. (2024). Hereditary tyrosinemia type 1. Orphanet.
